Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Transfusion-related cost and time burden offsets associated with pacritinib versus best available therapy in patients with myelofibrosis: an economic evaluation based on the PERSIST-2 trial.

Created on 12 Nov 2026

Authors

Aaron T Gerds, Abiola Oladapo, Karisse Roman-Torres, Stephen T Oh

Published in

Future oncology (London, England). Pages 1-9. Nov 11, 2026. Epub Nov 11, 2026.

Abstract

In the PERSIST-2 trial (NCT02055781), pacritinib (PAC) demonstrated significant anemia benefit versus best available therapy (BAT). This analysis aimed to estimate projected differences in transfusion-related cost and time burden with PAC versus BAT from a US payer perspective.
An economic evaluation was conducted using red blood cell (RBC) transfusion-related data of patients treated with PAC or BAT from PERSIST-2 trial. Transfusion status (transfusion independent [TI] or non-TI) at baseline (90 days pre-randomization) and during the study (over any 12-week interval through week 24) was defined using Gale criteria. Mean 30-day RBC transfusion rates were annualized and used as proxy for transfusion-related visits. Annual transfusion-related cost/time burden per patient by transfusion status were estimated.
Annual transfusion-related cost and time burden with PAC were projected to be 19.5% and 25.3% lower than with BAT ($252,057 vs $312,969; 507.9 vs 680.4 hours), with per patient cost and time savings of $60,912 and 172.4 hours, respectively. Patients who were non-TI at baseline had higher projected annual cost ($73,095/patient) and time savings (204.3 hours/patient) for PAC versus BAT.
Reduced transfusion rates with PAC versus BAT were projected to decrease transfusion-related medical costs and time burden in patients with cytopenic MF.

PMID:
43016247
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement